Your browser doesn't support javascript.
The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City.
Cedro-Tanda, Alberto; Gómez-Romero, Laura; Alcaraz, Nicolás; de Anda-Jauregui, Guillermo; Peñaloza, Fernando; Moreno, Bernardo; Escobar-Arrazola, Marco A; Ramirez-Vega, Oscar A; Munguia-Garza, Paulina; Garcia-Cardenas, Francisco; Cisneros-Villanueva, Mireya; Moreno-Camacho, Jose L; Rodriguez-Gallegos, Jorge; Luna-Ruiz Esparza, Marco A; Fernández Rojas, Miguel A; Mendoza-Vargas, Alfredo; Reyes-Grajeda, Juan Pablo; Campos-Romero, Abraham; Angulo, Ofelia; Ruiz, Rosaura; Sheinbaum-Pardo, Claudia; Sifuentes-Osornio, José; Kershenobich, David; Hidalgo-Miranda, Alfredo; Herrera, Luis A.
  • Cedro-Tanda A; Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico.
  • Gómez-Romero L; Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico.
  • Alcaraz N; Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico.
  • de Anda-Jauregui G; Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico.
  • Peñaloza F; Cátedras CONACYT para Jóvenes Investigadores, CONACYT, Av. de los Insurgentes Sur 1582, Crédito Constructor, Benito Juárez, Mexico City 03940, Mexico.
  • Moreno B; Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico.
  • Escobar-Arrazola MA; Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico.
  • Ramirez-Vega OA; Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico.
  • Munguia-Garza P; Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico.
  • Garcia-Cardenas F; Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico.
  • Cisneros-Villanueva M; Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico.
  • Moreno-Camacho JL; Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico.
  • Rodriguez-Gallegos J; Clinical Laboratory Division, Salud Digna, Culiacan, Sinaloa 80000, Mexico.
  • Luna-Ruiz Esparza MA; Clinical Laboratory Division, Salud Digna, Culiacan, Sinaloa 80000, Mexico.
  • Fernández Rojas MA; Molecular Biology Laboratory, National Reference Center, Salud Digna, Tlalnepantla de Baz, Estado de Mexico 54075, Mexico.
  • Mendoza-Vargas A; Innovation and Research Department, Salud Digna, Culiacan, Sinaloa 80000, Mexico.
  • Reyes-Grajeda JP; Innovation and Research Department, Salud Digna, Culiacan, Sinaloa 80000, Mexico.
  • Campos-Romero A; Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico.
  • Angulo O; Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico.
  • Ruiz R; Innovation and Research Department, Salud Digna, Culiacan, Sinaloa 80000, Mexico.
  • Sheinbaum-Pardo C; Secretaría de Educación, Ciencia, Tecnología e Innovacion, Av Chapultepec 49, Colonia Centro, Cuauhtémoc, Mexico City 06010, Mexico.
  • Sifuentes-Osornio J; Secretaría de Educación, Ciencia, Tecnología e Innovacion, Av Chapultepec 49, Colonia Centro, Cuauhtémoc, Mexico City 06010, Mexico.
  • Kershenobich D; Gobierno de la Ciudad de México, Antiguo Palacio del Ayuntamiento, Avenida Plaza de la Constitución 2, Colonia Centro, Mexico City 06010, Mexico.
  • Hidalgo-Miranda A; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico.
  • Herrera LA; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico.
Viruses ; 13(11)2021 10 29.
Article in English | MEDLINE | ID: covidwho-1488760
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The SARS-CoV-2 pandemic is one of the most concerning health problems around the globe. We reported the emergence of SARS-CoV-2 variant B.1.1.519 in Mexico City. We reported the effective reproduction number (Rt) of B.1.1.519 and presented evidence of its geographical origin based on phylogenetic analysis. We also studied its evolution via haplotype analysis and identified the most recurrent haplotypes. Finally, we studied the clinical impact of B.1.1.519. The B.1.1.519 variant was predominant between November 2020 and May 2021, reaching 90% of all cases sequenced in February 2021. It is characterized by three amino acid changes in the spike protein T478K, P681H, and T732A. Its Rt varies between 0.5 and 2.9. Its geographical origin remain to be investigated. Patients infected with variant B.1.1.519 showed a highly significant adjusted odds ratio (aOR) increase of 1.85 over non-B.1.1.519 patients for developing a severe/critical outcome (p = 0.000296, 1.33-2.6 95% CI) and a 2.35-fold increase for hospitalization (p = 0.005, 1.32-4.34 95% CI). The continuous monitoring of this and other variants will be required to control the ongoing pandemic as it evolves.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Humans Country/Region as subject: Mexico Language: English Year: 2021 Document Type: Article Affiliation country: V13112182

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Humans Country/Region as subject: Mexico Language: English Year: 2021 Document Type: Article Affiliation country: V13112182